Brief: Onxeo Net Result Turns To Loss Of EUR 4.8 Mln

Valerio Therapeutics SA

29/07/2021 17:36

July 29 (Reuters) - ONXEO SA  ALONX.PA :
    * CASH POSITION OF €24.5 MILLION AS OF JUNE 30, 2021
    * FINANCIAL VISIBILITY UNTIL THE END OF 2022
    * PREPARING AN AMBITIOUS CLINICAL PLAN FOR ASIDNA™, WITH
IMPLEMENTATION TO BE INITIATED IN FALL OF 2021
    * H1 NET LOSS EUR 4.8 MILLION VERSUS PROFIT EUR 5.0 MILLION
YEAR
AGO
    * CONSOLIDATED REVENUES FOR THE PERIOD ENDED JUNE 30, 2021,
AMOUNTED TO 0.6 MILLION EUROS
    * H1 OPERATING LOSS AFTER EQUITY METHOD INCOME EUR 4,547
THOUSAND
    * THE GROUP'S CASH POSITION ON JUNE 30, 2021, WAS 24.5
MILLION
EUROS, COMPARED WITH 14.5 MILLION EUROS AT  DECEMBER 31, 2020

Source text for Eikon:  ID:nNDL2rR9JT 
Further company coverage:  ALONX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))